The Critical Medicines Act (CMA) addresses supply chain vulnerabilities by redefining procurement criteria, emphasizing quality, security, and environmental standards. European manufacturers gain ...
In the first part of this interview, Romanski tells PharmTech Group that while the field of oral dosage forms has not grown ...
As a part of its CPHI Frankfurt 2025 coverage, Pharmaceutical Technology ® interviewed Sriman Banerjee, PhD, executive ...
In this PharmTech video feature, we highlight the week’s industry news in an easy-to-consume, fun format. New roundups will ...
Maggie Saykali, Cefic, explains that Western pharma vulnerability stems from market loss to Asia, caused largely by ...
As Thermo Fisher’s Jennifer Cannon explains in this first part of a two-part interview, the collaboration is intended to help ...
J.D. Mowery, Bora, says tariffs localize biopharma supply chains, the "biotech freeze" mandates robust data, and AI rapidly ...
CPHI Pharma Awards 2025 recognized innovations in bio/pharmaceutical development, emphasizing sustainability, drug delivery, ...
Nigel Langley of gChem stresses excipient innovation, safer solvents, and supply chain resilience for pharma’s future in part ...
AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...
In this part 2 of a 2-part interview regarding the presentation “Beyond Traditional Markets: The Strategic Importance of ...
Pharmaceutical Technology® spoke with Dr. Weite Oldenziel, CEO of Ofichem, before CPHI Frankfurt 2025 to get his perspective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback